Highlights

  • Nexalis has screened the first patient in the Phase 2 trial of IRX-211.
  • The study targets approximately 156 patients with breakthrough cancer pain.
  • The company is advancing three clinical-stage therapeutic programs.
  • Recent corporate activity included a funding facility update and temporary trading suspension.

Nexalis Therapeutics Ltd (ASX:NX1) has reached a clinical development milestone after screening the first patient in its Phase 2 study of IRX-211, an inhaled therapy for breakthrough cancer pain. The announcement marks the transition of the lead candidate into efficacy testing following earlier Phase 1 safety studies. Alongside IRX-211, the company continues progressing two additional drug candidates, although all three programs remain in clinical development and are yet to receive regulatory approval.

IRX-211 Enters Phase 2 Evaluation

The Phase 2 study is designed as a randomised, double-blind, placebo-controlled crossover trial involving approximately 156 patients with breakthrough cancer pain.

IRX-211 is an inhaled formulation of dronabinol (synthetic THC) intended to provide rapid pain relief for opioid-tolerant cancer patients.

The trial follows a Phase 1 program in healthy volunteers, where the company reported a favourable safety profile and consistent pharmacokinetic results.

While screening the first patient represents an operational milestone, the study has not yet generated efficacy data.

Broader Pipeline Continues to Progress

In addition to IRX-211, Nexalis is developing IRX-616a, an inhaled cannabidiol therapy for panic disorder.

The company reported that IRX-616a completed dosing in its final Phase 1 cohort during May 2026, with topline results expected to guide the next stage of development.

A third program, SRX-25, is being developed as an oral esketamine therapy for treatment-resistant depression.

All three candidates are being developed using the US FDA's 505(b)(2) regulatory pathway.

Funding and Corporate Developments Remain in Focus

Nexalis has funded its clinical pipeline through capital raisings and financing facilities.

During May 2026, the company entered a trading halt, followed by a temporary suspension before returning to quotation after announcing a binding letter of intent relating to a funding facility.

The company also lodged a further update regarding its funding facility and clinical program during July 2026.

Future quarterly reports are expected to provide updated information on cash resources and funding capacity.

Clinical Progress Will Drive Future Milestones

The immediate focus is expected to remain on patient enrolment and progression through the Phase 2 IRX-211 study.

Investors are also likely to monitor topline Phase 1 results for IRX-616a and any regulatory developments relating to SRX-25.

As a clinical-stage biotechnology company, future progress will depend on successful trial outcomes, regulatory advancement and continued access to funding.

Upcoming ASX announcements are expected to provide updates on clinical milestones, financing and pipeline development.

What Investors May Watch

Investors may monitor patient enrolment in the IRX-211 Phase 2 study, Phase 1 results for IRX-616a, funding updates, regulatory developments and future ASX announcements.

Risks

Nexalis Therapeutics remains exposed to clinical trial risk, regulatory uncertainty, funding requirements, shareholder dilution, development delays and the possibility that its therapies may not demonstrate sufficient efficacy or obtain regulatory approval.